betaxolol has been researched along with Capsule Opacification in 1 studies
Capsule Opacification: Clouding or loss of transparency of the posterior lens capsule, usually following CATARACT extraction.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a double masked randomised clinical trial, 38 eyes from 38 pseudophakic patients over 21 years of age who had significant posterior capsule opacification after phacoemulsification were randomly assigned to receive either betaxolol 0." | 5.51 | The prophylactic effect of betaxolol 0.5% versus brimonidine 0.2% on IOP elevation after Nd:YAG laser posterior capsulotomy. ( Elmi Sadr, N; Paknazar, F; Saber, E, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Elmi Sadr, N | 1 |
| Saber, E | 1 |
| Paknazar, F | 1 |
1 trial available for betaxolol and Capsule Opacification
| Article | Year |
|---|---|
The prophylactic effect of betaxolol 0.5% versus brimonidine 0.2% on IOP elevation after Nd:YAG laser posterior capsulotomy.
Topics: Betaxolol; Brimonidine Tartrate; Capsule Opacification; Glaucoma; Humans; Intraocular Pressure; Lens | 2022 |